MCID: SPR013
MIFTS: 37

Spiradenoma malady

Categories: Rare diseases, Cancer diseases, Skin diseases, Ear diseases

Aliases & Classifications for Spiradenoma

About this section

Aliases & Descriptions for Spiradenoma:

Name: Spiradenoma 11 13
Eccrine Spiradenoma 11 46 66
Benign Eccrine Spiradenoma 11 46
 
Eccrine Spiradenoma, Benign 46
Eccrine Spiradenoma of Skin 11
Es 46

Classifications:



External Ids:

Disease Ontology11 DOID:5444
SNOMED-CT60 403938001, 4977000
NCIt43 C4170

Summaries for Spiradenoma

About this section
Wikipedia:69 Spiradenoma, also spiroma or eccrine spiradenoma, is a cutaneous condition that is typically... more...

MalaCards based summary: Spiradenoma, also known as eccrine spiradenoma, is related to syringoma and malignant spiradenoma. An important gene associated with Spiradenoma is CYLD (CYLD Lysine 63 Deubiquitinase), and among its related pathways are Striated Muscle Contraction and EGFR Signaling Pathway. Affiliated tissues include skin, breast and t cells.

Related Diseases for Spiradenoma

About this section

Diseases in the Spiradenoma family:

Malignant Spiradenoma

Diseases related to Spiradenoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 197)
idRelated DiseaseScoreTop Affiliating Genes
1syringoma29.9MUC1, VIM
2malignant spiradenoma12.3
3benign eccrine breast spiradenoma11.9
4breast malignant eccrine spiradenoma11.9
5adnexal spiradenoma/cylindroma of a sweat gland11.9
6ewing sarcoma11.3
7brooke-spiegler syndrome10.9
8glomangioma10.6CYLD, TP53
9simple partial epilepsy10.4ACTC1, TP53
10sm-ahnmd10.4TP53, VIM
11kidney sarcoma10.4TP53, VIM
12hypoglossal nerve neoplasm10.4S100B, TP53
13infantile glycine encephalopathy10.4ACTC1, S100B
14hypotonia10.4S100B, VIM
15exstrophy-epispadias complex10.4S100B, VIM
16absence of fingerprints congenital milia10.4S100B, VIM
17diffuse pulmonary fibrosis10.4ACTC1, S100B
18adenofibroma10.4TP53, VIM
19fraxf syndrome10.4S100B, VIM
20spastic ataxia 310.4TP53, VIM
21malignant cystic nephroma10.4S100B, VIM
22malignant adenofibroma10.3S100B, VIM
23benign intermediate mesothelioma10.3CYLD, KRT14
24epithelioid cell melanoma10.3S100B, VIM
25lymphangiomatosis10.3ACTC1, VIM
26myxoid liposarcoma of the ovary10.3ACTC1, VIM
27iridogoniodysgenesis and skeletal anomalies10.3ACTC1, VIM
28skin lipoma10.3ACTC1, VIM
29sialolithiasis10.3ACTC1, TP53
30pauciarticular onset juvenile idiopathic arthritis10.3S100B, VIM
31osteopetrosis and infantile neuroaxonal dystrophy10.3S100B, VIM
32mollaret meningitis10.3ACTC1, VIM
33small intestinal sarcoma10.3ACTC1, TP53
34malignant peritoneal solitary fibrous tumor10.3ACTC1, VIM
35connective tissue benign neoplasm10.3CYLD, KRT14
36malignant glandular tumor of peripheral nerve sheath10.3ACTC1, VIM
37papillary adenoma10.3CYLD, KRT14
38cribriform carcinoma10.3KRT14, TP53
39protoplasmic astrocytoma10.3S100B, TP53
40t-cell childhood acute lymphocytic leukemia10.2ACTC1, VIM
41retroperitoneal germ cell neoplasm10.2TP53, VIM
42amelogenesis imperfecta local hypoplastic10.2KRT14, VIM
43mature b-cell neoplasm10.2KRT14, TP53
44anal squamous cell carcinoma10.2KRT14, TP53
45localized epiphyseal dysplasia10.2ACTC1, TP53
46oligoastrocytoma10.2KRT14, VIM
47ductal carcinoma in situ10.2KRT14, TP53
48frontal sinus squamous cell carcinoma10.1ACTC1, VIM
49epidural neoplasm10.1ACTC1, VIM
50bullous keratopathy10.1KRT14, TP53

Graphical network of the top 20 diseases related to Spiradenoma:



Diseases related to spiradenoma

Symptoms for Spiradenoma

About this section

Drugs & Therapeutics for Spiradenoma

About this section

FDA approved drugs:

id Drug Name Active Ingredient(s)16 Company Approval Date
1
Erbitux16 42 CETUXIMAB Imclone, Bristol-Myers Squibb February 2004
FDA Label: Erbitux
Disease/s that Drug Treats:Colorectal Cancer
Indications and Usage:16 Erbitux® is an epidermal growth factor receptor (EGFR) antagonist indicatedfor treatment of:Head and Neck Cancer Locally or regionally advanced squamous cell carcinoma of the headand neck in combination with radiation therapy. (1.1, 14.1) Recurrent locoregional disease or metastatic squamous cell carcinomaof the head and neck in combination with platinum-based therapy with5-FU. (1.1, 14.1) Recurrent or metastatic squamous cell carcinoma of the head and neckprogressing after platinum-based therapy. (1.1, 14.1)Colorectal CancerK-Ras wild-type, EGFR-expressing, metastatic colorectal cancer asdetermined by FDA-approved tests in combination with FOLFIRI for first-line treatment, in combination with irinotecan in patients who are refractory toirinotecan-based chemotherapy, as a single agent in patients who have failed oxaliplatin- andirinotecan-based chemotherapy or who are intolerant to irinotecan.(1.2, 5.7, 12.1, 14.2)Limitation of Use: Erbitux is not indicated for treatment of Ras-mutantcolorectal cancer. (5.7, 14.2)
DrugBank Targets:14 1. Epidermal growth factor receptor;2. Low affinity immunoglobulin gamma Fc region receptor III-B;3. Complement C1r subcomponent;4. Complement C1q subcomponent subunit A;5. Complement C1q subcomponent subunit B;6. Complement C1q subcomponent subunit C;7. Low affinity immunoglobulin gamma Fc region receptor III-A;8. Complement C1s subcomponent;9. High affinity immunoglobulin gamma Fc receptor I;10. Low affinity immunoglobulin gamma Fc region receptor II-a;11. Low affinity immunoglobulin gamma Fc region receptor II-b;12. Low affinity immunoglobulin gamma Fc region receptor II-c
Mechanism of Action:16 
Target: binding of epidermal growth factor (EGF) and other ligands to epidermal growth factor receptor (EGFR, HER1, c-ErbB-1)
Action: inhibitor
FDA: The epidermal growth factor receptor (EGFR, HER1, c-ErbB-1) is a transmembraneglycoprotein that is a member of a subfamily of type I receptor tyrosine kinases including EGFR,HER2, HER3, and HER4. The EGFR is constitutively expressed in many normal epithelialtissues, including the skin and hair follicle. Expression of EGFR is also detected in many humancancers including those of the head and neck, colon, and rectum. Cetuximab binds specifically to the EGFR on both normal and tumor cells, and competitivelyinhibits the binding of epidermal growth factor (EGF) and other ligands, such as transforminggrowth factor-alpha. In vitro assays and in vivo animal studies have shown that binding ofcetuximab to the EGFR blocks phosphorylation and activation of receptor-associated kinases,resulting in inhibition of cell growth, induction of apoptosis, and decreased matrixmetalloproteinase and vascular endothelial growth factor production. Signal transduction throughthe EGFR results in activation of wild-type Ras proteins, but in cells with activating Ras somaticmutations, the resulting mutant Ras proteins are continuously active regardless of EGFRregulation.In vitro, cetuximab can mediate antibody-dependent cellular cytotoxicity (ADCC) against certainhuman tumor types. In vitro assays and in vivo animal studies have shown that cetuximabinhibits the growth and survival of tumor cells that express the EGFR. No anti-tumor effects ofcetuximab were observed in human tumor xenografts lacking EGFR expression. The addition ofcetuximab to radiation therapy or irinotecan in human tumor xenograft models in mice resultedin an increase in anti-tumor effects compared to radiation therapy or chemotherapy alone.
2
Evista16 42 RALOXIFENE HYDROCHLORIDE Eli Lilly September 2007
FDA Label: Evista
Disease/s that Drug Treats:osteoporosis and reduction of breast cancer risk in postmenopausal women
Indications and Usage:16 EVISTA is an estrogen agonist/antagonist indicated for Treatment and prevention of osteoporosis in postmenopausal women.(1.1)
DrugBank Targets:14 1. Estrogen receptor;2. Estrogen receptor beta
Mechanism of Action:16 
Target: estrogenic pathways
Action: can be an activator or antooagonist
FDA: Decreases in estrogen levels after oophorectomy or menopause lead to increases in bone resorption andaccelerated bone loss. Bone is initially lost rapidly because the compensatory increase in bone formation isinadequate to offset resorptive losses. In addition to loss of estrogen, this imbalance between resorption andformation may be due to age-related impairment of osteoblasts or their precursors. In some women, these changeswill eventually lead to decreased bone mass, osteoporosis, and increased risk for fractures, particularly of the spine,hip, and wrist. Vertebral fractures are the most common type of osteoporotic fracture in postmenopausal women.The biological actions of raloxifene are largely mediated through binding to estrogen receptors. This bindingresults in activation of certain estrogenic pathways and blockade of others. Thus, raloxifene is an estrogenagonist/antagonist, commonly referred to as a selective estrogen receptor modulator (SERM).Raloxifene decreases resorption of bone and reduces biochemical markers of bone turnover to thepremenopausal range. These effects on bone are manifested as reductions in the serum and urine levels of boneturnover markers, decreases in bone resorption based on radiocalcium kinetics studies, increases in bone mineraldensity (BMD), and decreases in incidence of fractures.
3
Istodax16 42 ROMIDEPSIN Gloucester Pharmaceuticals November 2009
FDA Label: Istodax
Disease/s that Drug Treats:cutaneous T-cell lymphoma
Indications and Usage:16 ISTODAX is a histone deacetylase (HDAC) inhibitor indicated for: Treatment of cutaneous T-cell lymphoma (CTCL) in patients who havereceived at least one prior systemic therapy (1). Treatment of peripheral T-cell lymphoma (PTCL) in patients who havereceived at least one prior therapy (1).These indications are based on response rate. Clinical benefit such asimprovement in overall survival has not been demonstrated (1).
DrugBank Targets:14 -
Mechanism of Action:16 
Target: histone deacetylase (HDAC)
Action: inhibitor
FDA: Romidepsin is a histone deacetylase (HDAC) inhibitor. HDACs catalyze the removal of acetyl groups from acetylated lysine residues in histones, resulting in themodulation of gene expression. HDACs also deacetylate non-histone proteins, such as transcription factors. In vitro, romidepsin causes the accumulation of acetylatedhistones, and induces cell cycle arrest and apoptosis of some cancer cell lines with IC50 values in the nanomolar range. The mechanism of the antineoplastic effect ofromidepsin observed in nonclinical and clinical studies has not been fully characterized.
4
Treanda16 42 BENDAMUSTINE HYDROCHLORIDE Cephalon October 2008
FDA Label: Treanda
Disease/s that Drug Treats:Chronic lymphocytic leukemia and B-cell non-Hodgkin’s lymphoma
Indications and Usage:16 TREANDA is an alkylating drug indicated for treatment of patients with: Chronic lymphocytic leukemia (CLL). Efficacy relative to first linetherapies other than chlorambucil has not been established. (1.1) Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed duringor within six months of treatment with rituximab or a rituximab-containingregimen. (1.2)
DrugBank Targets: -
Mechanism of Action:16 
Target: -
Action: -
FDA: Bendamustine is a bifunctional mechlorethamine derivative containing a purine-like benzimidazole ring.Mechlorethamine and its derivatives form electrophilic alkyl groups. These groups form covalent bonds with electronrichnucleophilic moieties, resulting in interstrand DNA crosslinks. The bifunctional covalent linkage can lead to celldeath via several pathways. Bendamustine is active against both quiescent and dividing cells. The exact mechanism ofaction of bendamustine remains unknown.

Interventional clinical trials:

Search ClinicalTrials, NIH Clinical Center for Spiradenoma

Genetic Tests for Spiradenoma

About this section

Anatomical Context for Spiradenoma

About this section

MalaCards organs/tissues related to Spiradenoma:

34
Skin, Breast, T cells, B cells, Endothelial, Bone, Testes

Animal Models for Spiradenoma or affiliated genes

About this section

Publications for Spiradenoma

About this section

Articles related to Spiradenoma:

(show top 50)    (show all 162)
idTitleAuthorsYear
1
A rare case of eccrine spiradenoma-treatment and management. (27069311)
2016
2
Giant vascular eccrine spiradenoma of the leg: MR imaging findings. (27397887)
2016
3
Malignant Spiradenoma: a Giant Cutaneous Adnexal Tumor. (26563774)
2015
4
Spiradenocarcinoma in Preexisting Spiradenoma With a Large In Situ Adenocarcinoma Component. (25830720)
2015
5
Eccrine Spiradenoma Arising from the Breast Skin. (26236527)
2015
6
Giant Vascular Eccrine Spiradenoma. (26365030)
2015
7
Inexplicable Co- Existence of Eccrine Spiradenoma and Lichen Planus in an old Case of Basal Cell Carcinoma. (25737995)
2015
8
Sonographic and sonoelastographic findings of a rarely seen soft tissue tumor: eccrine spiradenoma. (26576987)
2015
9
Spiradenoma and cylindroma originate from the hair follicle bulge and not from the eccrine sweat gland: an immunohistochemical study with CD200 and other stem cell markers. (25354097)
2014
10
Giant vascular eccrine spiradenoma. (22148049)
2011
11
A rare case of giant malignant eccrine spiradenoma. (21342314)
2011
12
Expression of p53 and TP53 mutational analysis in malignant neoplasms arising in preexisting spiradenoma, cylindroma, and spiradenocylindroma, sporadic or associated with Brooke-Spiegler syndrome. (20075707)
2010
13
Not all stubbed toes are innocuous--A case report of rare malignant eccrine spiradenoma (spiradenocarcinoma) of the toe. (20483125)
2010
14
Carcinoma ex spiradenoma/cylindroma confirmed by immunohistochemical and molecular loss-of-heterozygosity profiling. (19684510)
2009
15
Eccrine spiradenoma with chondroid syringoma in Blaschkoid distribution. (19915242)
2009
16
Malignant eccrine spiradenoma on the lateral margin of nose as an infrequent localization. (20101314)
2009
17
Morphologic diversity of malignant neoplasms arising in preexisting spiradenoma, cylindroma, and spiradenocylindroma based on the study of 24 cases, sporadic or occurring in the setting of Brooke-Spiegler syndrome. (19194280)
2009
18
A case of eccrine spiradenoma arising in nevus sebaceous in an adolescent girl. (18360132)
2008
19
Eccrine spiradenoma: co-expression of cytokeratin and smooth muscle actin suggesting differentiation toward myoepithelial cells. (17207189)
2007
20
Giant vascular eccrine spiradenoma: report of a case with immunohistochemical study. (16479087)
2006
21
De novo malignant eccrine spiradenoma: a case report and review of the literature. (16970705)
2006
22
Malignant eccrine spiradenoma of the vulva: a case report and review of the literature. (16803551)
2006
23
Congenital blaschkoid eccrine spiradenoma on the face. (15757814)
2005
24
Brooke-Spiegler syndrome associated with cylindroma, trichoepithelioma, spiradenoma, and syringoma. (14739501)
2004
25
Spiradenocarcinoma of the breast arising in a long-standing spiradenoma. (15185264)
2004
26
Eccrine spiradenoma: an unusual presentation with otalgia. (14990930)
2004
27
Malignant eccrine spiradenoma: a case report with pulmonary metastasis. (14989745)
2004
28
Two cases of multiple eccrine spiradenoma with linear or localized formation. (15492423)
2004
29
Multiple eccrine spiradenoma in zosteriform distribution. (12960891)
2003
30
Malignant eccrine spiradenoma occurring on a traumatized area. (12087301)
2002
31
Malignant eccrine spiradenoma: an unusual presentation. (17656974)
2002
32
Malignant eccrine spiradenoma. (11958666)
2002
33
Malignant eccrine spiradenoma of the neck: a case report. (11593191)
2001
34
Extensive naevoid eccrine spiradenoma. (10215788)
1999
35
Spiradenoma arising in a nevus sebaceus of Jadassohn: case report and literature review. (10535577)
1999
36
Carcinosarcoma arising in eccrine spiradenoma of the breast. Report of a case and review of the literature. (8639057)
1996
37
Cutaneous adnexal carcinoma arising within a solitary cylindroma-spiradenoma. (8721596)
1996
38
Eccrine spiradenoma, not poroma. (8634818)
1996
39
An unusual, recurring breast tumor with features of eccrine spiradenoma: a case report. (8929479)
1996
40
Dermal cylindroma and eccrine spiradenoma. (8936072)
1996
41
An unusual case of early malignant transformation in a spiradenoma. (7633823)
1995
42
An uncommon breast tumour: the malignant eccrine spiradenoma. A case report. (8140844)
1993
43
Malignant eccrine spiradenoma. A clinicopathologic study. (1384379)
1992
44
Sweat gland carcinoma ex eccrine spiradenoma. (2847574)
1987
45
Multiple linear eccrine spiradenoma associated with multiple trichoepithelioma. (3038978)
1987
46
Eccrine spiradenoma: clinical and pathologic study of 49 tumors. (6313776)
1983
47
Eccrine spiradenoma and dermal cylindroma. (6302142)
1983
48
Eccrine spiradenoma. (4168808)
1967
49
Eccrine spiradenoma. Histochemical and electron microscopic studies. (4286974)
1966
50
Eccrine spiradenoma; report of a case and preliminary pharmacologic studies. (13423892)
1957

Variations for Spiradenoma

About this section

Expression for genes affiliated with Spiradenoma

About this section
Search GEO for disease gene expression data for Spiradenoma.

Pathways for genes affiliated with Spiradenoma

About this section

Pathways related to Spiradenoma according to GeneCards Suite gene sharing:

idSuper pathwaysScoreTop Affiliating Genes
19.3ACTC1, VIM
29.2MUC1, TP53

GO Terms for genes affiliated with Spiradenoma

About this section

Biological processes related to Spiradenoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorGO:00069789.7MUC1, TP53
2DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestGO:00069779.6MUC1, TP53
3muscle filament slidingGO:00300499.3ACTC1, VIM
4positive regulation of gene expressionGO:00106288.9ACTC1, TP53, VIM

Molecular functions related to Spiradenoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1keratin filament bindingGO:19902549.8KRT14, VIM
2p53 bindingGO:00020399.2MUC1, TP53

Sources for Spiradenoma

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
25GTR
26HGMD
27HMDB
28ICD10
29ICD10 via Orphanet
30ICD9CM
31IUPHAR
32KEGG
35MedGen
37MeSH
38MESH via Orphanet
39MGI
42NCI
43NCIt
44NDF-RT
47NINDS
48Novoseek
50OMIM
51OMIM via Orphanet
55PubMed
56QIAGEN
61SNOMED-CT via Orphanet
65Tumor Gene Family of Databases
66UMLS
67UMLS via Orphanet